Fresenius Medical Care AG
FMSHealthcareNASDAQMedical Care Facilities · Last scanned Sep 8, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Fresenius Medical Care AG focuses on Medical Care Facilities services and products. Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. With a market capitalization of $12.06B, it sits in large-cap territory. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Market Cap
$12.06B
Beta
0.83
P/E (TTM)
11.80
P/E (Fwd)
6.21
EPS (TTM)
$1.92
EPS (Fwd)
$3.65
ROE
8.5%
ROA
4.0%
Cash
$1.06B
Total Debt
$10.98B
Free CF
$2.02B
52W Change
-10.4%
Annual Financials
Cash vs Debt
Where FMS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FMS finished 0.04% above its 150-day moving average ($22.64) and 0.44% above its 200-day moving average ($22.55). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FMS overbought or oversold?
At the September 3, 2026 close, FMS's RSI(14) was 27.1, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $1.06B in cash, though total debt stands at $10.98B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company generates $2.02B in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of 8.5% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.0% is on the lower side, which is common in asset-heavy industries. Revenue has been uneven over recent years, ranging from $17.62B to $19.63B.
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing FMS.